English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Monoamine oxidase-B (MAO-B) is a mitochondrial protein located in the outer mitochondrial layer [1,2] and catalyzes the metabolism of neurotransmitters such as dopamine. Monoamine oxidase-B has therefore been of interest in the development of therapeutic agents for the treatment of Parkinson’s disease [3,4]. In Parkinson’s disease, there is a loss of dopaminergic neurons of the striatum leading to the characteristic movement associated symptoms. Inhibition of MAO-B leads to increased levels of dopamine and therefore provides symptomatic relief for these patients. Because MAO-B degrades dopamine and at the same time produces toxic by-products such as hydrogen peroxide and ammonia [5], inhibition of MAO-B is effective in alleviating the symptoms of Parkinson’s disease [6]. Monoamine oxidase has been divided into two subtypes [7], MAO-A and MAO-B, on the basis of their amino acid sequence, substrate and inhibitor selectivity and tissue distribution. Monoamine oxidase-A inhibitors are prescribed for the treatment of mental depression and anxiety [8], while monoamine oxidase-B inhibitors are used with L-DOPA and/or dopamine agonists in the symptomatic treatment of Parkinson’s disease. Parkinson’s disease is a common neurodegenerative disorder that affects about 1 % of the population over the age of 60 years [9]. The disease is characterized by the loss of dopamine neurons in the substantia nigra and the formation of inclusions, called Lewy bodies, in the midbrain [10]. Iron accumulation in the substantia nigra of Parkinson’s disease patients was initially described 80 years ago [11]. Iron as a Interaction of Monoamine Oxidase-B with a Series of Coumarin by Molecular Modeling Methods